<DOC>
	<DOC>NCT00661167</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of tri-weekly ABI-007 for recurrence or unresectable gastric cancer patients who have received one prior regimen containing fluoropyrimidine and developed disease progression or recurrence.</brief_summary>
	<brief_title>Phase II Study of ABI-007 for Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Histologically or cytologically confirmed gastric adenocarcinoma Received one prior regimen containing fluoropyrimidine analogs and developed disease progression or recurrence Age: 20 74 At least one measurable lesion by RECIST criteria History of Taxans use Patients with another active malignancy Preexisting peripheral neuropathy of Grade 2, 3, or 4 (per CTCAE) Chronic treatment with steroids</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>